Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Intervalo de año
1.
PLoS One ; 17(10): e0275488, 2022.
Artículo en Inglés | MEDLINE | ID: covidwho-2054385

RESUMEN

Glutaraldehyde, a germicide for reprocessing endoscopes that is important for hygiene in the clinic, might be hazardous to humans. Electrolyzed acid water (EAW) has a broad anti-microbial spectrum and safety profile and might be a glutaraldehyde alternative. We sought to assess EAW disinfection of flexible endoscopes in clinical otorhinolaryngological settings and its in vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and bacteria commonly isolated in otorhinolaryngology. Ninety endoscopes were tested for bacterial contamination before and after endoscope disinfection with EAW. The species and strains of bacteria were studied. The in vitro inactivation of bacteria and SARS-CoV-2 by EAW was investigated to determine the efficacy of endoscope disinfection. More than 20 colony-forming units of bacteria at one or more sampling sites were detected in 75/90 microbiological cultures of samples from clinically used endoscopes (83.3%). The most common genus detected was Staphylococcus followed by Cutibacterium and Corynebacterium at all sites including the ears, noses, and throats. In the in vitro study, more than 107 CFU/mL of all bacterial species examined were reduced to below the detection limit (<10 CFU/mL) within 30 s after contact with EAW. When SARS-CoV-2 was treated with a 99-fold volume of EAW, the initial viral titer (> 105 PFU) was decreased to less than 5 PFU. Effective inactivation of SARS-CoV-2 was also observed with a 19:1 ratio of EAW to the virus. EAW effectively reprocessed flexible endoscopes contributing to infection control in medical institutions in the era of the coronavirus disease 2019 pandemic.


Asunto(s)
COVID-19 , Desinfección , Bacterias , COVID-19/prevención & control , Estudios Transversales , Endoscopios/microbiología , Endoscopios Gastrointestinales/microbiología , Contaminación de Equipos/prevención & control , Glutaral , Humanos , SARS-CoV-2 , Agua
2.
JPRN; 20/12/2021; TrialID: JPRN-jRCT1030210501
Clinical Trial Register | ICTRP | ID: ictrp-JPRN-jRCT1030210501

RESUMEN

Condition:

not specified

Primary outcome:

The percentage of suspected and confirmed COVID-19 patients to the total number of patients visiting the preoperative clinic

Criteria:

Inclusion criteria: Patients who were scheduled to visit the preoperative clinic between January 1st, 2020 and September 30th, 2021.

Exclusion criteria: Patients who canceled their preoperative clinic visitation for unknown reasons.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA